Viking Therapeutics Reports Strong 2025 Growth Amid Market Volatility
Viking Therapeutics, Inc. (VKTX) demonstrated robust financial performance in 2025, with revenue surging 21.9% to $6.5 billion. Adjusted net income jumped 43.9% to $1.17 billion, while EBITDA climbed 38.8% to $1.87 billion. The company's net yield improved 7.4% to $583, signaling operational efficiency gains.
Fourth-quarter results outpaced expectations with 27.8% revenue growth, driven by a 14.7% increase in passenger cruise days. Advance bookings for 2026 ROSE 13% to $5.96 billion, suggesting sustained demand despite broader market headwinds.
Notably, VKTX shares dipped 1.48% to $33.34 post-announcement, reflecting investor caution in the current biotech climate. The disconnect between fundamentals and market reaction mirrors patterns seen in crypto assets like BTC and ETH during periods of institutional repositioning.
